BRIEF-National Advisory Committee On Immunization Recommends RSV Vaccines, Including Arexvy, For Older Adult Populations July 16 (Reuters) - GSK plc GSK.L : NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION (NACI) RECOMMENDS RSV VACCINES, INCLUDING AREXVY, FOR OLDER ADULT POPULATIONS GSK: RSV VACCINATION RECOMMENDED FOR CONSIDERATION BY ADULTS AGED 60 TO

Second malaria vaccine launched in Ivory Coast in new milestone By Maggie Fick LONDON, July 15 (Reuters) - The world's second vaccine against malaria was launched on Monday as Ivory Coast began a routine vaccine programme using shots developed by the University of Oxford and the Serum Institute of India. The introduction of the World Health Organization (WHO)-approved R21 vaccine comes six months after the first malaria vaccine, called RTS,S and developed by British drugmaker GSK GSK.L , began b

BRIEF-German Cartel Office: GSK Cleared To Buy Curevac Assets July 12 (Reuters) - CureVac NV 5CV.DE : GERMAN CARTEL OFFICE: GSK CLEARED TO BUY CUREVAC ASSETS Source text Further company coverage: 5CV.DE

BRIEF-GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season July 11 (Reuters) - GSK plc GSK.L : GSK BEGINS SHIPPING INFLUENZA VACCINE DOSES FOR 2024-25 SEASON GSK: EXPECTS TO DISTRIBUTE OVER 36 MILLION DOSES OF ITS TRIVALENT INFLUENZA VACCINES IN US THIS SEASON Source text for Eikon: ID:nBw7xSr4xa Further company coverage: GSK.L

EUROPE RESEARCH ROUNDUP-Diageo, Publicis, Wolters Kluwer NV July 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Diageo, Publicis and Wolters Kluwer NV, on Thursday. HIGHLIGHTS * Diageo DGE.L : HSBC cuts target price to 3,300p from 3,500p * Mfe-Mediaforeurope NV MFEB.MI : JP Morgan raises to overweight from neutral * Prosiebensat 1 Media SE PSMGn.DE : JP Morgan raises to overweight from neutral * Publicis PUBP.PA : JP Morgan cuts

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births By Christy Santhosh July 8 (Reuters) - Pfizer's PFE.N respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots. The vaccine Abrysvo was approved by the U.S.

BUZZ-Top of the Street: GSK, Melrose Industries, Arkema, B&M A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Five-star ranked RBC Capital Market's analyst Mark Fielding raises Melrose Industries MRON.L to "outperform" from "sector perform", seeing fundamentals remaining very supportive despite shares underperforming in the past months, and expecting further earnings upgrades ** J.P.Morgan raises Arkema AKE.PA to "neutral" from "underweight", seeing buysi

EUROPE RESEARCH ROUNDUP-Glencore, Rio Tinto, Michelin July 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Glencore, Rio Tinto and Michelin, on Monday. HIGHLIGHTS * Arkema SA AKE.PA : JP Morgan raises to neutral from underweight * Glencore GLEN.L : Jefferies raises target price to 600p from 550p * Michelin MICP.PA : HSBC raises to buy from hold * Pirelli & C SpA PIRC.MI : HSBC raises to buy from hold * Rio Tinto RIO.L : Jefferies

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p

PRESS DIGEST-British Business - July 4 July 4 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Dublin-based video game services group Keywords Studios KWS.L has agreed to a bid worth 2.2 billion pounds ($2.80 billion) from European private equity firm EQT EQTAB.ST - A partnership between GSK GSK.L and CureVac 5CV.DE struck during the pandemic has been restructured i

PRESS DIGEST- Financial Times - July 4 July 4 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - EQT strikes 2.2 bln STG deal for Irish video gaming group Keywords Studios - Hawksmoor restaurant chain up for sale - Germany vetoes sale of sensitive turbine unit to Chinese group - GSK signs 1.4 bln euros mRNA vaccine deal with troubled biotech CureVac Overview - A consortium led by Swedish

Deals of the day-Mergers and acquisitions Adds: Quest Diagnostics, Lufthansa, CoinDCX Updates: Volkswagen July 3 (Reuters - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday: ** Quest Diagnostics DGX.N said it would acquire Canada-based LifeLabs from pension plan owner OMERS for about C$1.35 billion, or about $985 million, including net debt.

Deals of the day-Mergers and acquisitions July 3 (Reuters - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Wednesday: ** Germany's cabinet blocked the planned sale of Volkswagen VOWG_p.DE subsidiary MAN Energy Solutions' gas turbine division to a Chinese company, two government sources said. nS8N3IC08R ** A joint venture between Trafigura and the Frontier Group of Companies (FGC) has completed its acquisition of the Mountain Creek power plant from a group of

BUZZ-CureVac soars on COVID, influenza vaccines deal with GSK ** Frankfurt-listed shares in CureVac 5CV.DE jump around 24% after British drugmaker GSK GSK.L said it will take control of several vaccines the two companies were jointly developing ** GSK said it will pay CureVac 400 million euros ($430.12 million) upfront and up to an additional 1.05

UPDATE 1-UK Stocks-Factors to watch on July 3 Adds new items, updates futures July 3 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0 .7%. * GSK: GSK GSK.L has bought from CureVac 5CV.DE , CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said.

UPDATE 3-GSK buys COVID, influenza vaccines from retrenching CureVac Adds details on CureVac throughout July 3 (Reuters) - British drugmaker GSK GSK.L on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the German biotech company's financial lifeline.

BRIEF-Gsk PLC - Gsk And Curevac Collaboration Restructured GSK plc GSK.L : GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED GSK PLC - ACQUIRES FULL RIGHTS TO DEVELOP VACCINES GSK - CUREVAC RECEIVES EUR 400 MILLION UPFRONT AND UP TO AN ADDITIONAL EUR 1.05 BILLION GSK - GSK WILL ASSUME FULL CON

GSK buys full rights to make COVID, influenza vaccines from CureVac July 3 (Reuters) - GSK GSK.L has bought the full rights to develop and manufacture mRNA-based candidate vaccines for influenza and COVID-19 from CureVac for up to 1.05 billion euros ($1.13 billion), it said on Wednesday. GSK and CureVac started collaborating in 2020 to develop mRNA-based vaccines for infectious diseases.

Health Rounds: Weight gain from various antidepressants varies slightly Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here . By Nancy Lapid July 2 (Reuters) - Hello Health Rounds Readers! Antidepressants have long been associated with weight gain, but today we have a study that finds little difference among a wide variety of the drugs.

BUZZ-US drugmakers fall as Biden urges price cuts on obesity drugs ** Shares of U.S. drugmakers down between 1% and 2% after President Joe Biden and Senator Bernie Sanders, in an opinion piece on USA Today, called out Eli Lilly LLY.N and Novo Nordisk NOVOb.CO to reduce high costs of their weight loss drugs ** They also pointed to high prices of all medicines across the United States compared to other nations ** U.S.